Early blood pressure outcomes after SPYRAL™ renal denervation: an exploratory small cohort analysis
6 affiliations
- 1Friedrich-Alexander-Universität Erlangen-Nürnberg , ,
- 2Die MSH Medical School Hamburg–University of Applied Sciences and Medical University , ,
- 3Clinic for Cardiology and Angiology, Helios Clinics Schwerin , ,
- 4University Clinic of Cardiology , ,
- 5Department of Internal Medicine III–Cardiology, Angiology, and Internal Intensive Care, Saarland University Medical Center , , ,
- 6Med. Klinik II-Kardiologie und Angiologie, Sana Kliniken , ,
Abstract
Background: Catheter-based renal denervation (RDN) is an interventional therapy for patients with resistant or uncontrolled arterial hypertension after the exclusion of secondary causes. This study aimed to evaluate the effects of the SPYRAL™ catheter system on systolic (SBP) and diastolic blood pressure (DBP) in a real-world clinical setting. Additionally, we explored whether the number of ablation points was associated with the magnitude of blood pressure (BP) reduction.
Methods: We conducted a retrospective, single-center study including patients aged ≥18 years with predominantly resistant hypertension with preserved renal function (eGFR ≥40 mL/min/1.73 m2) and no evidence of secondary hypertension. Ambulatory blood pressure monitoring (ABPM) and renal function were assessed at baseline and three months after RDN. Patients were stratified into subgroups based on the number of ablation points (≤20 vs. >20). A two-tailed p -value <0.05 was considered statistically significant.
Results: Data from eleven patients (mean age 64.4 ± 8.1, 45.5% were male) were analyzed. At three months, eGFR remained stable (mean decrease −4.6 mL/min/1.73 m ² , CI 95% −15.8–6.6, p = 0.37). Mean ambulatory SBP and DBP decreased significantly following RDN ( Δ −19.4mmHg, CI 95% −9.2 to −29.7, p = 0.002; Δ −8.6 mmHg, CI 95% −3.9 to −13.3, p = 0.002; for SBP and DBP respectively). Subgroup analysis revealed that patients with more ablation points experienced a greater reduction in SBP ( Δ −17.7 mmHg, CI 95% 0.1–35.3, p = 0.04) and a numerically greater reduction in DBP ( Δ −4.8 mmHg, CI 95% 4.5–12, p = 0.27) than those with fewer abation points.
Conclusion: In this small retrospective cohort, reductions in SBP and DBP were observed following RDN using the SPYRAL™ multi-electrode system, with no excess of adverse renal events. These preliminary findings require confirmation in larger, adequately powered patient cohorts before firm conclusions can be established.
Related
- Twelve-month outcomes and exploratory outcome indicators after iRoot BP Plus pulpotomy in primary molars: a retrospective real-world cohort study
- Short-term clinical outcomes of nasoduodenal tube versus feeding jejunostomy after minimally invasive esophagectomy: a retrospective cohort study with exploratory microbiome analysis
- Operative efficiency and short-term outcomes of da Vinci 5 versus da Vinci Xi in robotic rectal cancer surgery: an overlap-weighted cohort study with an exploratory case insights analysis
- Speech and acoustic outcomes after maxillary reconstruction with an anterolateral thigh flap: a prospective exploratory cohort study
- Pathological complete response and long-term outcomes after neoadjuvant therapy for breast cancer: a multicenter retrospective cohort study with exploratory subtype analyses
BibTeX
@article{stanisavljevikj2026early,
title = {{Early blood pressure outcomes after SPYRAL™ renal denervation: an exploratory small cohort analysis}},
author = {Sasho Stanisavljevikj and Ali Anwar and Ahmed Abu Rumman and Hristijan Alagjozovski and Vladyslav Kavalerchyk and Ivica Bojovski and Davor Vukadinović and Joachim Weil and Alexander Staudt},
journal = {Frontiers in cardiovascular medicine},
year = {2026},
month = oct,
doi = {10.3389/fcvm.2026.1934448},
url = {https://europepmc.org/article/PMC/PMC13670513},
note = {CC BY},
}
RIS
TY - JOUR
TI - Early blood pressure outcomes after SPYRAL™ renal denervation: an exploratory small cohort analysis
AU - Sasho Stanisavljevikj
AU - Ali Anwar
AU - Ahmed Abu Rumman
AU - Hristijan Alagjozovski
AU - Vladyslav Kavalerchyk
AU - Ivica Bojovski
AU - Davor Vukadinović
AU - Joachim Weil
AU - Alexander Staudt
PY - 2026
DA - 2026/10/01
JO - Frontiers in cardiovascular medicine
DO - 10.3389/fcvm.2026.1934448
UR - https://europepmc.org/article/PMC/PMC13670513
AB - Background: Catheter-based renal denervation (RDN) is an interventional therapy for patients with resistant or uncontrolled arterial hypertension after the exclusion of secondary causes. This study aimed to evaluate the effects of the SPYRAL™ catheter system on systolic (SBP) and diastolic blood pressure (DBP) in a real-world clinical setting. Additionally, we explored whether the number of ablation points was associated with the magnitude of blood pressure (BP) reduction. Methods: We conducted a retrospective, single-center study including patients aged ≥18 years with predominantly resistant hypertension with preserved renal function (eGFR ≥40 mL/min/1.73 m2) and no evidence of secondary hypertension. Ambulatory blood pressure monitoring (ABPM) and renal function were assessed at baseline and three months after RDN. Patients were stratified into subgroups based on the number of ablation points (≤20 vs. >20). A two-tailed p -value <0.05 was considered statistically significant. Results: Data from eleven patients (mean age 64.4 ± 8.1, 45.5% were male) were analyzed. At three months, eGFR remained stable (mean decrease −4.6 mL/min/1.73 m ² , CI 95% −15.8–6.6, p = 0.37). Mean ambulatory SBP and DBP decreased significantly following RDN ( Δ −19.4mmHg, CI 95% −9.2 to −29.7, p = 0.002; Δ −8.6 mmHg, CI 95% −3.9 to −13.3, p = 0.002; for SBP and DBP respectively). Subgroup analysis revealed that patients with more ablation points experienced a greater reduction in SBP ( Δ −17.7 mmHg, CI 95% 0.1–35.3, p = 0.04) and a numerically greater reduction in DBP ( Δ −4.8 mmHg, CI 95% 4.5–12, p = 0.27) than those with fewer abation points. Conclusion: In this small retrospective cohort, reductions in SBP and DBP were observed following RDN using the SPYRAL™ multi-electrode system, with no excess of adverse renal events. These preliminary findings require confirmation in larger, adequately powered patient cohorts before firm conclusions can be established.
SN - 2297-055X
ER -